BioPharma Resources

Drug Trial Radar · NCT03758716

An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Apr 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

12

Actual

Start

Jul 3, 2017

Primary completion

Jan 28, 2019

Study completion Sep 19, 2019

Sponsor

Lead sponsor
Fountain Biopharma Inc.Industry
Sponsor type
Industry
First posted
Nov 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the Safety and Efficacy of FB825 in Adults with Atopic Dermatitis

Conditions

  • Atopic Dermatitis

Interventions

  • FB825, FB825-15D11, Anti-CemXDrug

    Pharmaceutical form: 20mg/ml solution Route of administration: IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. % Change From Baseline in Total IgETime frame: Day 169
  2. % Change From Baseline in Allergen-specific IgETime frame: Day 169

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Taiwan University Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.